Exelixis Stock Price and Value Analysis

Should you buy Exelixis stock? (NasdaqGS:EXEL). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the EXEL Numbers

EXEL Price
(Exelixis stock price per share)
$15.80
[?] PE Ratio versus Sector 122% higher than other Healthcare stocks
[?] PE Ratio versus Industry 21% lower than other Biotechnology stocks
[?] Cash Yield -2.81%
[?] Free Cash Flow Jitter 1672%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 9,335,058 shares shorted. With 298,824,030 shares available for purchase and an average trading volume over the past 10 trading days of 1,943,750, it would take at least 4.803 days for all of the short holders to cover their shorts.

Is Exelixis Stock on Sale?

Based on our analysis, we believe that you should not buy Exelixis right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy EXEL Stock?

Does Exelixis have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.